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Background: Ultrasound guided sampling of human lymph node (LN) combined with
advanced flow cytometry allows phenotypic analysis of multiple immune cell subsets.
These may provide insights into immune processes and responses to immunotherapies
not apparent from analysis of the blood.
Methods: Ultrasound guided inguinal LN samples were obtained by both fine needle
aspiration (FNA) and core needle biopsy in 10 adults within 8 weeks of diagnosis of type
1 diabetes (T1D) and 12 age-matched healthy controls at two study centers. Peripheral
blood mononuclear cells (PBMC) were obtained on the same occasion. Samples
were transported same day to the central laboratory and analyzed by multicolour
flow cytometry.
Results: LN sampling was well-tolerated and yielded sufficient cells for analysis
in 95% of cases. We confirmed the segregation of CD69+ cells into LN and the
predominance of CD8+ Temra cells in blood previously reported. In addition, we
demonstrated clear enrichment of CD8+ naïve, FOXP3+ Treg, class-switched B cells,
CD56bright NK cells and plasmacytoid dendritic cells (DC) in LNs as well as CD4+
T cells of the Th2 phenotype and those expressing Helios and Ki67. Conventional
NK cells were virtually absent from LNs as were Th22 and Th1Th17 cells. Paired
correlation analysis of blood and LN in the same individuals indicated that for many cell
subsets, especially those associated with activation: such as CD25+ and proliferating
(Ki67+) T cells, activated follicular helper T cells and class-switched B cells, levels in
the LN compartment could not be predicted by analysis of blood. We also observed
an increase in Th1-like Treg and less proliferating (Ki67+) CD4+ T cells in LN from
T1D compared to control LNs, changes which were not reflected in the blood.
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Conclusions: LN sampling in humans is well-tolerated. We provide the first detailed
“roadmap” comparing immune subsets in LN vs. blood emphasizing a role for
differentiated effector T cells in the blood and T cell regulation, B cell activation and
memory in the LN. For many subsets, frequencies in blood, did not correlate with LN,
suggesting that LN sampling would be valuable for monitoring immuno-therapies where
these subsets may be impacted.
Keywords: type 1 diabetes, autoimmunity, lymph node, biomarker, immune monitoring
INTRODUCTION
Type 1 diabetes (T1D) is an autoimmune disease in which a
key component of the immune pathology is mediated by T cells
(1, 2). Although the disease process is focused on the pancreatic
islets, these are not accessible for monitoring in human T1D and
therefore studies have focused on changes apparent in the blood.
Despite multiple studies, consistent differences in circulating
lymphocyte subpopulations between subjects with and without
T1D, including those around disease onset, have been difficult
to define. Reports of differences in frequency in CD4+, CD8+,
T follicular helper (Tfh) cells, and subsets of regulatory T cells
(Treg) in subjects with new onset T1D (NOT1D) have not always
been confirmed although qualitative differences appear to exist
(3–8). Extensive efforts have also been directed to monitor islet
antigen-specific T cells using techniques including proliferation,
cytokine production, ELISPOTs and tetramer stainings with
some success (9–17). However, these assays remain challenging
due to the low frequency of antigen-specific T cells in the blood
(18). The situation is further complicated by the generation of
neoepitopes (19, 20).
Lymph nodes (LNs) are important sites in the body where
either an immune response to pathogenic antigens or tolerance
is initiated (21). In murine models, LNs are routinely used to
monitor the immune system as they are easier to access than
sampling blood. In the non-obese (NOD) mouse model of T1D
islet-specific T cells can be detected in the pancreatic LN before
the onset of disease (22) and removal of these LN rescues NOD
mice from developing T1D (23). Antigen-specific T cells have
also been isolated from pancreatic LNs in humans using organ
donor material (24), but this approach cannot be used for serial
monitoring. A recent report compared T cell subsets in LNs
from organ donors with and without diabetes and reported an
increase in Th17 cells and a reduction in Treg (25). However, this
did not relate to newly-diagnosed subjects with T1D. Indeed, it
has been noted that the pancreatic LN architecture is different
in individuals recently diagnosed with T1D, showing a loss
of germinal centers and fewer follicular dendritic cell (DC)
networks, although the exact significance is unclear (26).
It is possible to serially sample LNs in humans under
ultrasound guidance either by fine needle aspiration (FNA) or
core biopsy, and this technique is widely practiced in oncology.
We recently reported that this approach can detect antigen-
specific T cell activation after PPD challenge intradermally
(27). Although draining LNs of the target organ could ideally
be studied, for systemic autoimmune disease the approach of
sampling “distant” LNs (e.g., inguinal) has been used to monitor
disease in subjects with rheumatoid arthritis (RA) (28). The
authors examined the cellular composition of inguinal lymph
nodes (iLNs) in healthy volunteers, by flow cytometry, compared
to that from subjects with early RA and individuals at risk of
developing RA and showed significant changes in B, CD4+,
and CD8+ T cell composition by flow cytometry analysis
between groups. These changes were different from those seen in
peripheral bloodmononuclear cells (PBMCs) (29, 30), suggesting
that studying the composition of immune cells in the iLN has
additional value in understanding molecular events in the early
phases of an autoimmune disease. Recently, it has been reported
in preclinical models of T1D that beta cell derived antigens
are released from the pancreas and taken up by other distant
LNs (31), suggesting that LNs may also reflect the ongoing
disease process.
Monitoring changes in LN populations may be of value for
pharmacodynamic analysis of the response to immune therapies,
appropriate drug dosing and optimization of risk-benefit
in the treatment of autoimmune diseases. Sphingosine-
1-phosphate (S1P) agonists (e.g., Fingolimod (FTY720),
Ozanimod, Etrasimod, and Amiselimod), as an example, cause
sustained downregulation of S1P receptors on lymphoid cells
(S1PR1-5) and potentially lymphatic endothelium resulting in
lymphopaenia due to sequestration of immune cells in LNs
(32). Abatacept (CTLA-4-Ig), which has recently shown success
in slowing disease progression in established T1D, binds to
CD80/CD86 on antigen presenting cells reducing their ability
to deliver co-stimulatory signals and activate T cells. Recent
studies have reported biomarkers associated with treatment
success including a change in the ratio of CD4+ central (Tcm)
and effector memory T (Tem) cells (33) and levels of activated
B cells (34) which may be due to sequestration of cells in LNs.
Furthermore, alemtuzumab (anti-CD52) results in profound
depletion of circulating T and B cells, but minimal loss of
immune memory responses. Studies in an animal model suggest
that this favorable effect is due to failure to effectively deplete
immune cells from compartments other than the blood including
bone marrow, spleen, and LN (35).
In the current study, we sought to investigate the
feasibility and safety of LN sampling as a method to study
immune phenotypes in individuals with an organ-specific
autoimmune disease—NOT1D—and matched controls.
Using multidimensional flow cytometry, we performed a
comprehensive analysis of a wide range of leukocytes in
paired blood and LN biopsies in order to identify important
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differences in the frequency, differentiation and activation status
of immune cells in the two different compartments that could
be relevant for immune interventions. We believe this provides
a valuable “roadmap” to indicate when LN sampling is likely
to be informative in the development of immunotherapy for
autoimmune and other immune-related diseases.
MATERIALS AND METHODS
Study Subjects
Subjects were recruited from two centers, University Hospital
Wales, Cardiff and Cambridge University Hospital Trust
Foundation (CUHFT), Cambridge, U.K.. Ethical approval for
this study was granted by Ethics committee and institutional
review board, and informed consent was obtained from all
subjects enrolled. The study was registered on ClinicalTrials.gov
(identifier: NCT02801942). Demographic of subjects screened
and enrolled is reported in Table 1. Subjects with T1D had
a diagnosis consistent with Type 1a (autoimmune) Diabetes
Mellitus (according to ADA and WHO criteria) and were
recruited within an interval of up to 8 weeks between the initial
diagnosis and the date of biopsy, with residual functioning beta
cells as measured by fasted C-peptide levels (≥0.15 nmol/L).
Subjects required insulin treatment for at least 7 days prior to
the day of biopsy and they were positive at screening for at
least one autoantibody associated with T1D (anti-GAD, anti-IA-
2, anti-ICA, anti-IAA, and anti-ZnT8) while negative for anti-
thyroid peroxidase, anti-tissue transglutaminase and anti-nuclear
antibodies. Control subjects had no family history of T1D or any
presence of T1D-associated autoantibodies. EDTA blood and iLN
FNA and core samples were obtained from 12 control subjects
and 10 age-matched individuals with T1D with an average age
of 29 and 27, respectively (age range = 19–38). Two follow-up
phone calls were carried out ∼2–4 days and 7–14 days after the
biopsy to enable detection of any post procedural complications
and subjects overall experience of the study.
Biopsy of iLN FNA and Core
Sampling of iLN was performed under local anesthetic cover
and with ultrasound guidance. Both FNA and 16-gauge core
biopsy samples were obtained following procedures similar to
that described by Tatovic et al. (27) and De hair et al. (36).
Using an aseptic technique, between 2 and 5mL of 1% local
anesthetic were injected intra and sub-epidermally, reaching the
US-identified LN. The FNA sample was obtained by using a 21-
gauge needle. Real-time visualization with ultrasound was used
to ensure the needle tip remained within the node. The needle
tip was then moved through the nodal cortex to maximize the
cell yield of the sample. Following the FNA procedure, a small
(2–3mm) skin incision was made and up to five 16-gauge core
biopsies were obtained using the Bard Mission needle or Temno
needle, both withmanual advance technique tominimize trauma.
After obtaining each core sample manual pressure was applied to
the area, and at the end of the procedure 5min of further pressure
was applied. This was to ensure hemostasis and reduce the risk of
subsequent hematoma formation. Adverse events were reported
and are detailed in Table 2.
TABLE 1 | Details of recruitment efficacy and demographic data of subjects
screened and enrolled in the study.
Number of subjects Control T1D Overall
Number of subjects planned, [N] 10 10 20
Number of subjects screened, [N] 23 20 43
Number of subjects biopsied, [N] 12 10 22
Number of subjects completed as
planned, [N] (% of biopsied)
12 (100) 10 (100) 22 (100)
Overall % success rate (%) 52 50 51
Demographics of enrolled
subjects
Control T1D Overall
Age in years [Mean (SD)] 28.6
(5.53)
27.0
(5.35)
27.9 (5.38)
Sex [N (%)]
Female 4 (33) 4 (40) 8 (36)
Male 8 (67) 6 (60) 14 (64)
BMI (kg/m2) [Mean (SD)] 24.89
(3.70)
22.68
(2.17)
23.89
(3.23)
Height (cm) [Mean (SD)] 174.1
(10.27)
173.4
(10.54)
173.8
(10.15)
Weight (kg) [Mean (SD)] 76.18
(17.82)
68.06
(7.60)
72.49
(14.43)
Ethnicity [N (%)]
Not hispanic or latino 12 (100) 10 (100) 22 (100)
Race [N (%)]
White—
White/Caucasian/European
Heritage
12 (100) 10 (100) 22 (100)
TABLE 2 | Table of adverse events.
Preferred term Control (n = 12) T1D (n = 10) Overall (n = 22)
Any event, n (%) 9 (75) 5 (50) 14 (64)
Procedural pain 6 (50) 4 (40) 10 (45)
Post procedural
contusion
4 (33) 4 (40) 8 (36)
Nausea 1 (8) 0 1 (5)
Fatigue 1 (8) 0 1 (5)
Sample Processing of iLN FNA and Core
Core iLN samples were homogenized through 70µm cell
strainers using 1mL syringe plungers. Both core and FNA
samples were washed in RPMI and counted using trypan blue.
If present, red blood cells were lysed using BD Pharm lysing
buffer (BD Pharmingen) and subsequently counted in Türk’s
solution. In all cases, viability was >95% and FNA and core
cell yields are reported in Table 3 [FNA average 0.72 × 106
(range 0.01–3.58× 106) cells; core average 0.67 × 106 (range
<0.01–3.50× 106)].
Flow Cytometric Analyses
Up to 1 million iLN FNA and core cells (minimum 10,000 cells)
were stained in PBS containing 0.2% BSA and 2mM EDTA using
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TABLE 3 | Operator dependent differences in numbers of cells from LN core and fine needle aspirate (FNA) biopsies. Low indicates <0.01 × 106 total cells.
Site Control/T1D Number
of
subjects
Gender Average age Average number of
LN FNA cells (×10∧6)
(range)
Number of LN
cores
Average number of
LN core cells (×10∧6)
(range)
Cardiff Control 7 4M 3F 30 0.96 (0.52–1.60) 4 0.83 (low−3.50)
Cardiff T1D 5 2M 3F 29 1.38 (0.06–3.58) 4 0.59 (0.21–1.21)
Cardiff Combined 12 6M 6F 29 1.13 (0.06–3.58) 4 0.72 (low−3.50)
CUC Control 5 4M 1F 27 0.40 (0.08–1.16) 3 0.16 (0.11–0.25)
CUC T1D 5 4M 1F 25 0.07 (0.01–0.22) 3 0.74 (0.52–1.37)
CUC Combined 10 8M 2F 26 0.23 (0.01–1.16) 3 0.45 (0.11–1.37)
Combined Control 12 8M 4F 29 0.72 (0.08–1.60) 3 0.53 (low−3.50)
Combined T1D 10 6M 4F 27 0.72 (0.01–3.58) 4 0.67 (0.21–1.37)
Combined Combined 22 14M 8F 28 0.72 (0.01–3.58) 3 0.67 (low−3.50)
three panels of antibodies, detailed in Supplementary Table 1.
Following cell surface staining, cells were fixed and permeabilised
using FOXP3/TF staining buffer kit (eBioscience) according
to manufacturer’s instructions, then stained for FOXP3, Ki67,
and Helios. 100–200 µL of EDTA blood was stained using the
same three panels of antibodies, however PerFix-nc buffer set
(Beckman Coulter) was used for intracellular staining. Blood
samples stained only with surface markers were lysed using
BD FACS lysing solution (BD Biosciences). Stained samples
were acquired on a BD LSRFortessa and data analyzed using
FlowJo software (LCC). CS&T beads were run daily and the
same machine, with the same cytometer configuration and
application settings, was used for the measurements of the
samples throughout the study.
Statistical Analyses
Research analysis plan, study results and primary statistical
analysis as per protocol are available at ClinicalTrials.gov
(Identifier: NCT02801942). In this manuscript we present a
post-hoc re-analysis to compare leukocyte frequencies between
tissue types and examine frequencies of selected leukocyte subsets
with particular relevance to the pathogenesis of T1D. Due
to low cell yield obtained from some iLN biopsy samples,
the method described by Henley and Keeney (37) was used
to exclude results where the number of events acquired was
insufficient for accurate enumeration (those with a theoretical
CV of ≥20%). Combined iLN data was calculated by taking
an average of the frequency data from FNA and core samples,
where both data were available. All data were analyzed using R
Studio statistical software environment and GraphPad Prism 8
software. Unbiased agglomerative hierarchical clustering analysis
was performed with scaled data on all subjects containing
complete data for all flow cytometric parameters using complete
linkage method and Pheatmap package. Principal component
analysis (PCA) was similarly performed using complete scaled
data, on a total of 61 populations using base R functions, ggplot2,
and Factoextra R packages in an unsupervised approach. When
analyzing the full data set to identify populations that differed
in frequency between tissues, paired Student’s t-tests were used
to compute p-values for all cell populations, correcting for
multiple testing using the Holm-Sidakmethod.When comparing
the frequency of individual populations of cells identified as
significant in the above analyses separately in T1D and control
groups, individual paired tests were used, either Student’s t-test
or Wilcoxon signed-rank test based on the normality of the
data. Differences in frequencies between samples from the same
tissue (blood or iLN) between individuals with or without T1D
were tested using unpaired tests (ANOVA or Kruskal-Wallis
test) correcting for testing multiple tissues using Holm-Sidak’s
or Dunn’s multiple comparison test as appropriate. However,
due to the low sample size in this study, these tests were not
corrected for testing multiple cell subsets. Within individual
correlation of cell population frequencies between blood and
iLN were calculated by Spearman’s rank correlation. Values of
p < 0.05 were considered statistically significant.
RESULTS
LN Biopsy to Investigate Biomarkers of
Disease Activity Is Safe, Tolerable and
Feasible in Individuals With New Onset T1D
Subject recruitment for this study was carried out at two centers,
the Clinical Research Facility at University Hospital Wales,
Cardiff (Cardiff), and Clinical Unit Cambridge (CUC). A total
of 43 subjects were screened (23 controls and 20 T1D subjects)
(Table 1), of which 22 subjects (12 controls and 10 T1D subjects)
met inclusion criteria, resulting in screening success rates of
52 and 50%, respectively. All 22 enrolled subjects underwent a
biopsy and completed the study as described in the Materials and
Methods. The biopsy procedures were very well-tolerated and no
serious complications were reported. However, eight contusions
spread equally across the control and T1D subjects were reported
throughout the study (following LN biopsy) and no hematoma
was reported or observed, in contrast to the hematoma rate of
80% reported in De hair et al. (36). Adverse events were reported
in 75 and 50% of control and T1D subjects, respectively, all of
which were mild in intensity except for a moderate event of
nausea reported by one control subject (Table 2). No serious
adverse events or any events leading to withdrawal were reported
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during the study. Overall, combined FNA followed by core biopsy
sampling was well-tolerated.
Sampling of both FNA and core biopsies were attempted from
all subjects, yielding on average 0.72× 106 (0.08–1.60× 106) and
0.72× 106 (0.01–3.58× 106) FNA cells and 0.53× 106 (<0.01×
106-3.50 × 106) and 0.67 × 106 (0.21–1.37 × 106) core iLN cells
from control and T1D subjects, respectively (Table 3), suggesting
that overall recovery of cells was similar between biopsy methods
and between sites.
Unbiased Analysis of Immune Cell
Subpopulations Suggests Cells Obtained
by FNA and Core Biopsy Methods Are
Indistinguishable
Flow cytometric staining was performed using three panels of
monoclonal antibodies designed to measure the frequency of T
cell, B cell, DC, monocyte, and NK cell subsets and to assess
activation and proliferation of T cells (example gating strategies
are shown in Supplementary Figure 1). As monocytes were only
observed in blood samples, these were excluded from analysis.
In total 61 subpopulations of leukocytes were enumerated from
at least one of the two iLN biopsies in all subjects. For some
individuals, insufficient cells were recovered from one of the iLN
biopsy methods to allow staining with all three antibody panels
to be carried out [9 FNA samples and 9 core samples, from
which 2 FNA and 1 core samples yielded too few cells to perform
any flow staining (7% failure rate)] and we therefore excluded
those samples from the following analysis. Unbiased hierarchical
clustering analysis of standardized population frequencies was
performed to investigate tissue-specific immune phenotypes and
a clustered heatmap of these analyses is shown in Figure 1.
Blood samples from all 22 individuals (subjects with and without
NOT1D) clustered together in a single clade while iLN FNA
and core samples were interspersed in another clade, suggesting
that immunophenotypes of blood samples are very different to
iLN samples and that cells isolated from FNA and core iLN
samples had indistinguishable phenotypes. In all cases where
sufficient cells were recovered from both iLN biopsies to allow
staining with all three panels of antibodies, samples from FNA
and core from an individual clustered next to one another, again
supporting the similarity of cell populations recovered by these
methods. Samples from individuals with T1D and controls were
interspersed in each of the two tissue-defined clades and showed
no significant disease-associated clustering. These findings
were confirmed using principle component analysis (PCA),
which revealed a distinct cluster of samples from blood but
overlapping clusters from FNA and core samples (Figure 2A).
Again, no major disease-associated clustering was observed.
The key leukocyte populations driving clustering in the PCA
was investigated using a loading plot (Figure 2B). PC1, which
describes 33.5% of the variation in the data andmay be thought of
as the main discriminator between blood and iLN biopsies, was
largely driven by differences in T cell subpopulations including
those defined by markers of activation, tissue retention and
polarization (such as Helios, CD69 and chemokine receptor
expression). In contrast, PC2, which describes 9.6% of the
variation and may be thought of as the main discriminator
between samples from different individuals, was driven mainly
by markers of immunological memory and antigen experience.
As these unbiased analyses demonstrated that samples from
FNA and core were indistinguishable, in all subsequent analyses
we used averaged values from FNA and core samples for each
subject (iLN).
Leukocyte Subsets Implicated in the
Pathogenesis of T1D Differ in Frequency
Between iLN and Blood
Next, we performed statistical analysis to identify individual cell
populations that differed in frequency between paired samples
from iLN and blood using either pooled data from control
and T1D subjects or stratifying the data by the two cohorts
(correcting for the multiple analyses performed). The results for
pooled data are displayed as a volcano plot in Figure 3A (raw
data in Supplementary Table 2) which indicates the relationship
between the fold difference in frequency of each cell population
between blood and iLN and the significance of the change.
There are significant changes in the distribution T and B
cell naïve/memory populations in all subjects (Figures 3B,C).
CD8+ T cells demonstrated a higher frequency of naïve and
lower frequency of terminally differentiated memory T cells
(TEMRA) in iLN compared to blood. In contrast, we observed no
difference in the frequency of naïve or memory subsets in CD4+
conventional T cells (i.e., non-Tregs; Tconv) but did note a shift
in the balance of resting/naïve vs. memory Treg cells, with the
former decreased in iLN samples. Higher frequencies of class-
switched B cells and lower naïve B cells were also observed in
iLN in all subjects. Furthermore, as reported by others (38), we
observed a significant reduction in the frequency of NK cells
(expressed as a proportion of total mononuclear leukocytes) in
iLN compared to blood, but a marked increase in the proportion
of NK cells expressing high levels of CD56 (Figure 3C). We also
noted a significant increase in the proportion of plasmacytoid
DC (pDC) and FOXP3+ Treg in iLN. All of these tissue-
specific differences in frequency were observed in both T1D and
control samples.
Chemokine Receptor Expression on CD4+
T Cells Differs Between iLN and Blood
Differential expression of chemokine receptors can be used to
identify CD4+ T cells with different helper function potential
(39). We therefore categorized CD4+ Tconv cells based on
patterns of chemokine expression (Figure 4) using the gating
scheme shown in Supplementary Figure 1. In all subjects,
we observed a significant increase in cells characterized by
expression of CCR4 in the absence of CXCR3, CCR6, CCR10,
or CXCR5 (Th2-like) in iLN compared to blood (Figure 4B).
By contrast, we observed a significant decrease in iLN in
subpopulations of cells characterized by expression of CCR6
including those co-expressing CCR10 (Th22) or CXCR3 (Th1-
Th17) in both cohorts (Figures 4C–E). Cells expressing CXCR5
were identified as Tfh and although they were detected at higher
frequency in iLN compared to blood when considering control
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FIGURE 1 | Cells from blood and iLN biopsies display distinct immune profiles. Unbiased Hierarchical clustered heatmap analysis of cell population frequencies (n =
61) in peripheral blood (PB), fine needle aspirates (FNA), and core biopsies (Core) from all control and T1D subjects (n = 12 and n = 10, respectively). The frequency of
each population was normalized to the mean frequency from all subjects and tissues and values represent the fold change from mean for each individual sample.
Control subjects or those with T1D are indicated with white and black symbols, respectively. Samples from PB, Core and FNA biopsies are depicted by red, light
green and dark green symbols, respectively. Individual sample identifiers are shown on the right of the plot indicating cohort group, subject number and biopsy type.
Tn, naïve T cells; Tcm, central memory T cells; Tem, effector memory T cells; Temra, Terminally differentiated T cells; Tscm, stem-cell memory-like T cells; rTreg, resting
Treg; mTreg, memory Treg; aTreg, activated Treg; Tfh, follicular helper cells; MNC, mononuclear cells; NK, natural killer cells; DC, dendritic cells. Frequencies of cell
populations were derived from the cell subset indicated in parentheses.
individuals, they were not significantly higher in iLN from
individuals with T1D or when the total cohort was analyzed
(Figure 4F and Supplementary Table 2).
Markers of Cellular Activation and
Proliferation Are Increased in T Cells From
iLN
Others have reported increased expression of the early
activation/tissue retention marker CD69 on CD8+ and CD4+
T cells from LNs compared to blood (27, 29, 30), a finding we
also observed and extended to FOXP3+ Tregs in both study
cohorts (Figures 5A–C). Similarly increased CD25 expression is
observed in both CD8+ and CD4+ Tconv cells in LNs compared
to blood (Supplementary Figure 2). In addition, in all subjects,
we observed an increase of markers of cellular activation in
iLN CD4+ T cells including ICOS and PD-1 co-expression in
Tfh and increased expression of the Helios transcription factor
in Tconv (Figures 5D,E). Interestingly, when we examined
expression of CD15s (Sialyl Lewis x), which identifies highly
differentiated and the most suppressive Tregs (40), we observed a
higher level of expression in iLN Tregs from control individuals
but did not observe this in subjects with T1D (Figure 5F).
Consistent with the LN being a major site for priming of T
cells, we also observed a significant increase in the proportion of
CD8+ and CD4+ Tconv cells expressing the marker of cellular
proliferation, Ki67, although this only reached significance for
the samples from control individuals and not for those with T1D
(Figures 5G,H). In contrast, no increase in Ki67 expression was
observed in Tregs from either study cohort or when all subjects
were analyzed together suggesting that, in contrast to non-Treg,
proliferation of FOXP3+ Tregs is not enriched in LNs compared
to blood (Figure 5I).
Some Cell Populations Show Strong
Correlation Between Frequency in Blood
and iLN, Others Show No Correlation
We examined within individual correlation of the frequency of
each cell subset between blood and iLN. This was to determine
whether, although differing in absolute frequency, assessing the
frequency of a particular cell population in blood would be a
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A
B
FIGURE 2 | Immune profiles in blood and iLN biopsies differ but cells from FNA and core biopsies are similar. Principle component analysis (PCA) was performed on
leukocyte subpopulation frequencies (n = 61) in peripheral blood (PB) and iLN biopsies. (A) Plot showing the two major principle components of leukocyte
subpopulation frequencies from blood, LN fine needle aspirates (FNA) and core biopsies (Core) from all control and T1D subjects (n = 12 and n = 10, respectively).
Individual samples identifiers are as explained in Figure 1. Shaded areas represent 95% confidence ellipses of the mean for each tissue. (B) Loading plot indicating
how strongly and in which direction each individual variables affect the two major principle components (PC1 and PC2). The top 27 variables contributing to PC1 and
PC2 are displayed and their relative influence expressed as a percentage (low% = orange, high% = blue) based on the average contribution of all variables to the PC.
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FIGURE 3 | Differences in immune cell subsets between blood and iLN in control and T1D subjects. (A) Volcano plot showing fold difference in the frequency of cell
populations on the x-axis and significance of the difference on the y-axis (-Log10 p-values) for blood and combined iLN from pooled control and T1D subjects.
P-values were calculated adjusting for multiple comparisons using the Holm-Sidak method. (B) Doughnut plots showing the distribution of naïve and memory CD8+
and CD4+ T cells, Treg and B cells in blood and iLN from pooled control and T1D subjects. Significance is calculated as described for panel A. (C) Paired frequencies
of key individual cell populations showing different frequencies in blood and iLN from control and T1D subjects. Student’s t-test or Wilcoxon signed-rank test was
used. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns, not significant; sw, switched.
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FIGURE 4 | Differences in chemokine receptor expression on memory CD4+ T cells between blood and iLN. (A–F) Paired frequencies of CD4+ helper T cell
populations in blood and iLN from control and T1D subjects. Frequencies of each cell type are expressed as a percentage of total memory CD4+ conventional T cells
(i.e., FOXP3− CD4+ T cells). Student’s t-test or Wilcoxon signed-rank test was used. *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.
good surrogate for the level in LN. This analysis revealed that
whilst for some populations there was good correlation between
the frequency observed in blood and iLN (e.g., CD4+ Tconv
central memory or Helios+ Treg), for other cell populations
there was little or no correlation between the frequency in blood
and iLN (e.g., naïve B cells or memory Treg) (Figure 6 and
Supplementary Table 3). Correlation was consistently poor in
all proliferating (Ki67+) T cells as well as other populations
characterized by recent activation, such as aTfh or aTreg.
Subtle Alterations in Treg Subsets Are
Observed in iLN but Not Blood in T1D
Several reports have noted alterations in the frequency of Treg
subsets in blood from individuals with new onset T1D including
markers of memory, activation and polarization (6, 41), however,
these differences are generally modest in size and hence require
large group sizes to detect them. Consistent with the majority of
studies, we did not observe a difference in the total frequency
of FOXP3+ Tregs in individuals with T1D in either blood or
iLN (Figure 7). We did, however, observe subtle differences in
the balance of Treg subsets in the iLN samples between control
and T1D subjects. Individuals with T1D had higher frequencies
of activated, antigen-experienced Tregs (defined as CD45RA−
FOXP3hi) (Figure 7A) and also a higher proportion of Th1-like
Tregs compared to these from control subjects (Figure 7B). No
such difference was observed between the two cohorts in helper T
subsets in either blood or iLN (Figure 7C). Finally, we observed a
lower proportion of CD4+ Tconv cells expressing Ki67, a marker
of cell proliferation, in iLN of individuals with T1D compared to
control subjects (Figure 7D). All of these differences were only
observed in iLN but not in blood samples.
DISCUSSION
The recirculation of lymphocytes was first described by
Gowans in 1959 (42) and emphasizes the dynamic interchange
between tissues, secondary LN organs, and blood. However,
the convenience of blood for sampling in humans has led
immunologists to largely ignore changes in the other immune
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FIGURE 5 | T cell subsets in iLN show enhanced expression of markers associated with activation, proliferation and tissue retention compared to blood. (A–I) Paired
frequencies of CD4+ helper T cell populations in blood and iLN from control and T1D subjects. Frequencies of each cell type are expressed as a percentage of total T
cell subtype. Student’s t-test or Wilcoxon signed-rank test was used. *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.
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FIGURE 6 | Some cell populations show strong correlation between frequency in blood and iLN, others show no correlation. (A) Within individual correlation of cell
population frequencies between blood and iLN was calculated using data from all individuals by Spearman’s rank correlation. Points are colored based on p-values
with those showing significant correlation (p < 0.05) shown in yellow-red symbols and those with no significant correlation shown in shades of green. (B–D) Example
correlation for individual cell subsets showing a high (B), medium (C), and no significant correlation (D) between frequencies in the blood and iLN.
compartments in studying immune responses and immune-
mediated diseases. Here we add to the limited literature on
human LN sampling to demonstrate that ultrasound guided LN
sampling is well-tolerated and can be reliably performed on LNs
that are not pathologically enlarged with a >95% success rate
when performed by experience radiologists. Both FNA and core
biopsy techniques are relatively low risk procedures, although
the former carries less risk of bleeding and is potentially more
suitable for repetitive sampling. However, whereas the FNA
provides only cytological information, core biopsy can provide
additional histological information. Furthermore, studies have
suggested that FNA biopsy may not accurately reflect the
composition of the whole LN due to sampling of selected regions
(43). Since excisional biopsy of iLN was not appropriate in this
context, we compared FNA with core biopsy, with an average
of 3 cores/individual, hypothesizing that core biopsy may be
more representative of the whole LN. However, we observed
no significant differences in the phenotype of cells obtained
from paired samples suggesting either technique yields similar
results. Comparison of blood and LN from the same individual
shows striking differences in the leukocyte populations present,
suggesting any blood contamination during the procedure
is minimal.
Advances in simultaneous multicolour flow cytometry in
recent years have allowed us to map differences in leukocyte
subpopulations between LN and blood in greater detail and
with greater resolution than was previously possible (27–30).
We have clearly shown that in the CD8+ T cell compartment,
naïve cells predominate in the LN while highly activated Temra
cells predominate in the blood confirming previous observations
(27). In the CD4+ T cell compartment, the frequency of naïve
and memory cells is similar in LN and blood, Temra cells are
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FIGURE 7 | Subtle alterations in the balance of T cell subpopulations between T1D and control individuals are evident in iLN but not in blood. Individual frequencies of
(A) naïve/memory Treg cell subsets (B), T helper-like Treg subsets (C), conventional helper T cell subsets, and (D) proliferation and activation marker on T cell subsets
in blood and iLN from control and T1D subjects. Frequencies of each cell type are expressed as a percentage of total T cell subtype. Error bars represent median and
inter quartile ranges for each population. ANOVA or Kruskal-Wallis test was used. *p<0.05. ns, not significant.
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rare in both compartments, but stem cell-like memory cells are
more common in LNs (Supplementary Table 2). Interestingly,
when expressed as a proportion of all CD4+ T cells, Tregs
are twice as frequent in LN than in blood and there is an
increase in the proportion of memory and decrease in resting
(or naïve) Tregs in LN compared to blood. By contrast, naïve
B cells are more frequent in the blood than in the LN while
class-switched memory B cells are more common in LNs. This
emphasizes a role for more differentiated effector T cells in the
blood while LNs appear to play a key role in CD4+ T cell
proliferation, T cell regulation, B cell activation and memory.
Treg function was compared by in vitro co-culture suppression
assays as previously described (44) using matched iLN and blood
samples. No difference in the suppressive capacity of Tregs
between tissues or between patients and controls were observed
(data not shown); however, due to the limited number of cells
isolated from non-pathologically enlarged iLN biopsies, we were
only able to perform assays on four subjects with T1D and 4
controls, limiting statistical power.
Other leukocyte subsets in addition to lymphocytes showed
polarization between blood and LN. The most striking example
is NK cells, in which conventional CD56dim NK cells are virtually
absent from LN while CD56bright NK cells are greatly enriched.
CD56bright NK cells are the major producer of NK cell cytokines
and constitutively express the high affinity heterotrimeric IL-
2 receptor making them responsive to picomolar levels of this
cytokine in vitro and in vivo (45). IL-2 treatment is currently
being tested to treat a variety of inflammatory and autoimmune
diseases by targeting Tregs (46), however, several studies have
shown that even using very low doses IL-2 treatment also
activates and expands the frequency CD56bright NK cells in
blood (44, 47) but to date no data is available on whether a
similar expansion is also seen in the LNs. The balance of DC
subpopulations is also altered between blood and iLN, with pDC
enriched in the latter. These cells are major producers of type 1
interferons in response to viral or other TLR ligands and play a
key role in activating CTL and Th1 responses. There is growing
evidence that numerical expansion or excessive activation of
pDCs may play a role in the pathogenesis of a number of
autoimmune conditions (48, 49) including T1D (50, 51), however
these studies have not investigated pDC phenotype or function
in LNs, the site where these cells are likely to directly influence
downstream adaptive immune responses.
The availability of additional T cell markers, especially
chemokine receptors, has allowed us to explore the functional
differences between the blood and LN compartments in more
detail than previously. In particular we observed that while Th1-
like cells are similarly distributed between blood and LN, Th2
cells are enriched in the LN (consistent with B cell activation).
A trend toward more Tfh cells is also observed in the LN. In
contrast, cell populations expressing CCR6 (especially Th1Th17
and Th22 cells) are enriched in the blood. CCR6-expressing
cells are thought to play a major role in a number of Th17-
mediated autoimmune diseases including T1D, psoriasis and RA
and targeting these cells or the cytokines they produce is an area
of active clinical trial activity (52, 53). In addition to confirming
the very high degree of segregation of CD69-expressing cells into
LNs (27, 30), we see an increase in other activation markers in
LN T cells, notably CD25, Helios and Ki67, even bearing in mind
that the LNs sampled were not selected to be actively involved in
an acute immune response.
Via comparative analysis of the correlation of blood and
LN levels across all different leukocyte subsets studied, we
have for the first time demonstrated that although blood
sampling is likely to provide a good indication of LN levels of
certain cell populations, for others it does not. Of particular
relevance to immune monitoring in settings of autoimmune and
inflammatory diseases or immunotherapy, we noted correlation
between blood and LN was consistently poor for all populations
of proliferating T cells and also other cell populations associated
with recent activation, such as ICOS+PD1+ Tfh (aTfh) and
CD45RA−FOXP3hi Treg (aTreg).We also noted poor correlation
for both CD4+ and CD8+ Tem cells as well as all B cell subsets.
Although subject numbers were small, limiting statistical
power, our study allowed us to compare T cell subsets in
LNs between subjects with active organ-specific autoimmunity
(NOT1D) and healthy age-matched controls. Consistent with
the relatively low levels of autoimmune T cell activation (54)
and the highly antigen-specific nature of T1D, any differences
in lymphocytes subsets were more modest than seen in previous
reports in RA (28, 29), where an increase in CD8+ memory
and antigen-experienced T cells in lymphoid tissue was seen
along with an increased frequency of non-circulating or recently
activated (CD69+) CD8+CD45RA+ T cells and an increased
frequency of (CD69+) CD8+CD45RO+ T cells in blood. In
our comparisons, no significant differences were seen for any
of the subsets in the blood between subjects with T1D and
controls. However, we did observe an increase in Th1-like Treg
and a reduction in proliferating (Ki67+) CD4+ and CD8+ T
cells in T1D LNs compared to control LNs. Interestingly, a
similar increase in Th1-like Tregs was recently described by
Viisanen et al. in the blood of children with NOT1D (55),
however the group sizes needed to reveal this difference (p= 0.01
with n= 73 T1D and n = 166 control) were much higher than
is used in this study supporting the hypothesis that, when
present, disease-associated immune phenotypes may be more
easily detected in LN than in the blood. A trend toward an
increase in activated Tfh cells in LN was observed, which is
possibly unexpected in view of the disruption of germinal centers
previously reported in pancreatic LNs in T1D (26). Note that the
significance of these changes has not been corrected for testing
multiple populations and hence should be viewed with caution.
Our results do provide the first “roadmap” of when LN
sampling would be most informative as predicted in Figure 6.
They suggest, for example, that blood monitoring of Treg
therapies (e.g., low dose IL-2), aimed at inducing Treg
proliferation, or depletion/repopulation therapies (such as anti-
thymocyte globulin or alemtuzumab), which aim to reset the
balance of memory-naive T cell subsets, may fail to represent
what is happening in the LNs. The samemay be true for the effects
of drugs that target CCR6 expressing (Th17-family) cells, such as
ustekinumab (which particularly targets Th1-Th17 cells), or anti-
CD20 therapies which target B cells or anti-CD3 which targets T
cells. Although our phenotyping was extensive, we did not obtain
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enough material to look for additional phenotypic indicators
such as cytokine expression. Ramwadhdoebe et al. reported
reduced IL-17 and interferon gamma positivity in CD8+ cells
from LN in RA but observed no changes in the blood. Finally, we
found it challenging, given the small size of the LN in NOT1D
and healthy controls to obtain informative histology from the
core biopsies. Future studies may allow single cell transcriptomic
analysis of LN-derived cells to provide additional information.
In summary, ultrasound guided LN sampling is well-
tolerated and has a high success rate in experienced hands.
Although differences in autoimmunity at the cell population
level are modest, it is likely to provide valuable information for
immunotherapy via cell manipulation and should be considered
in mechanistic analyses and targeted proof of pharmacology of
novel interventions.
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